AbbVie Reports Risankizumab Ulcerative Colitis Remission Rates at Week 96
AbbVie said risankizumab showed clinical remission rates of 54.0%–73.1% at week 96 in ulcerative colitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.